Microarray patches for managing infections at a global scale

Since the first patent for micro array patches (MAPs) was filed in the 1970s, research on utilising MAPs as a drug delivery system has progressed significantly, evidenced by the transition from the simple 'poke and patch' of solid MAPs to the development of bio responsive systems such as hydrogel-forming and dissolving MAPs. In addition to the extensive research on MAPs for improving transdermal drug delivery, there is a growing interest in using these devices to manage infectious diseases. This is due to the minimally invasive nature of this drug delivery platform which enable patients to self-administer therapeutics without the aid of healthcare pro-fessionals. This review aims to provide a critical analysis on the potential utility of MAPs in managing infectious diseases which are still endemic at a global scale. The range of diseases covered in this review include tuber-culosis, skin infections, malaria, methicillin-resistant Staphylococcus aureus infections and Covid-19. These dis-eases exert a considerable socioeconomic burden at a global scale with their impact magnified in low-and middle-income countries (LMICs). Due to the painless and minimally invasive nature of MAPs application, this technology also provides an efficient solution not only for the delivery of therapeutics but also for the administration of vaccine and prophylactic agents that could be used in preventing the spread and outbreak of emerging infections. Furthermore, the ability of MAPs to sample and collect dermal interstitial fluid that is rich in disease-related biomarkers could also open the avenue for MAPs to be utilised as a minimally invasive biosensor for the diagnosis of infectious diseases. The efficacy of MAPs along with the current limitations of such strategies to prevent and treat these infections will be discussed. Lastly, the clinical and translational hurdles associated with MAP technologies will also be critically discussed.

Automated summary

Since the 1970s, research on micro array patches (MAPs) for drug delivery has advanced from simple solid patches to bio responsive systems. In addition to improving transdermal drug delivery, there is growing interest in using MAPs to manage infectious diseases. MAPs offer a minimally invasive and self-administered solution, and they can also be used as biosensors for disease diagnosis. This review aims to analyze the potential utility of MAPs in managing infectious diseases such as tuberculosis, skin infections, malaria, methicillin-resistant Staphylococcus aureus infections, and Covid-19, and discuss their efficacy and limitations.